MTOR and neoplasm: Since the presence of an oncogenic mutation or a loss of tumour suppressor function does not dictate whether the cell uses all of the downstream signalling molecules for pathway activation [33,34], we determined the phosphorylation status of the immediate downstream substrates of the PI3K, mTOR and MAPK pathways.